LRMR Larimar Therapeutics (LRMR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001374690
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
101
13F, latest reported quarter
What the filings say about LRMR
Insiders, 180 days
+$166.9K net bought
1 buyer
Larimar Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Larimar Therapeutics, Inc. insiders bought a net $166.9K of stock across 27 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Feb 27, 2026.
- -4.8% median (-2.2% mean) 90-day return after 4 previous buys.
- The trade is 7.0% of the 714,798 shares held after it.
- No other insider bought within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hamilton Thomas Edward bought about $166.9K of LRMR on Jul 6, 2026; 101 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 31, 2025.
- +33.5% median (+33.5% mean) 90-day return after 2 previous buys.
- The trade is 10.2% of the 10,622,928 shares held after it.
- 3 other insiders bought within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Deerfield Mgmt HIF, L.P. bought about $5.4M of LRMR on Feb 27, 2026; 3 other insiders bought within 30 days and 101 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 31, 2025.
- +33.5% median (+33.5% mean) 90-day return after 2 previous buys.
- The trade is 32.2% of the 6,207,982 shares held after it.
- 3 other insiders bought within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Deerfield Mgmt HIF, L.P. bought about $10.0M of LRMR on Feb 27, 2026; 3 other insiders bought within 30 days and 101 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 31, 2025.
- +33.5% median (+33.5% mean) 90-day return after 2 previous buys.
- The trade is 10.2% of the 8,153,107 shares held after it.
- 3 other insiders bought within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Deerfield Mgmt HIF, L.P. bought about $4.2M of LRMR on Feb 27, 2026; 3 other insiders bought within 30 days and 101 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 31, 2025.
- +33.5% median (+33.5% mean) 90-day return after 2 previous buys.
- The trade is 10.2% of the 10,622,957 shares held after it.
- 3 other insiders bought within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Deerfield Mgmt HIF, L.P. bought about $5.4M of LRMR on Feb 27, 2026; 3 other insiders bought within 30 days and 101 funds added in the latest 13F quarter.27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$166.9K over 180 days
more than 80% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
101 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
26.6% of the float short (float per yahoo 2026-10-26) · 8.7 days to cover · settled 2026-09-30
more than 84% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LRMR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LRMR: institutional holders (13F)
13F holdings, latest reported quarter
35,606,974 sh
$108.6M
9,163,157 sh
$27.9M
5,678,035 sh
$17.3M
3,670,135 sh
$11.2M
3,163,423 sh
$9.6M
Congress trades in LRMR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LRMR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LRMR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Driehaus Micro Cap Growth Fund
$1.0M position · as of 2026-06-30
0.2%
GMO U.S. Small Cap Value Fund
$45.5K position · as of 2026-05-31
0.1%
Ultra-Small Company Market Fund
$106.5K position · as of 2026-06-30
0.1%
Adara Smaller Companies Fund
$573.4K position · as of 2026-05-31
0.1%
AQR Small Cap Multi-Style Fund
$232.6K position · as of 2026-06-30
0.1%
Federated Hermes MDT Small Cap Core ETF
$163.8K position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
1 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.5M
$2.1M
$1.5M
-64%
n/a
2024
$2.5M
$2.4M
$1.3M
-64%
n/a
2023
$3.1M
$3.3M
$1.4M
-58%
n/a
2022
$2.1M
-$437.3K
$1.1M
-62%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $166.9K bought by insiders over 180 days, 101 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LRMR financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2019-04-01 to 2020-03-31
Revenue, TTM LRMR
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM LRMR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM LRMR
| FY Dec 2025 | -$92.4M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -$19.4M |
| Mar 2025 | -$26.6M |
| Dec 2024 | -$22.0M |
| Sep 2024 | -$24.6M |
At each fiscal year end
Single quarter
Debt to equity
0.11x
long-term debt only, 2019-12-31 (79 months older than the period end); equity 2026-06-30
Debt to equity LRMR
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.23x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt LRMR
| FY Dec 2025 | -6.34x |
| FY Dec 2024 | -4.86x |
| FY Dec 2023 | -2.30x |
| FY Dec 2022 | -1.90x |
| FY Dec 2021 | -2.89x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -6.34x |
| Sep 2025 | -6.34x |
| Jun 2025 | -6.34x |
| Mar 2025 | -5.97x |
| Dec 2024 | -4.86x |
| Sep 2024 | -4.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-139.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LRMR
| FY Dec 2025 | -132.6% |
| FY Dec 2024 | -63.6% |
| FY Dec 2023 | -38.4% |
| FY Dec 2022 | -40.3% |
| FY Dec 2021 | -65.7% |
| Jun 2026 | -139.6% |
| Mar 2026 | -109.8% |
| Dec 2025 | -132.6% |
| Sep 2025 | -78.2% |
| Jun 2025 | -60.2% |
| Mar 2025 | -50.8% |
| Dec 2024 | -63.6% |
| Sep 2024 | -44.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-109.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LRMR
| FY Dec 2025 | -95.7% |
| FY Dec 2024 | -54.4% |
| FY Dec 2023 | -33.2% |
| FY Dec 2022 | -34.5% |
| FY Dec 2021 | -55.2% |
| Jun 2026 | -109.5% |
| Mar 2026 | -87.7% |
| Dec 2025 | -95.7% |
| Sep 2025 | -65.0% |
| Jun 2025 | -51.5% |
| Mar 2025 | -45.5% |
| Dec 2024 | -54.4% |
| Sep 2024 | -40.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LRMR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-140.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LRMR
| FY Dec 2025 | -134.3% |
| FY Dec 2024 | -69.3% |
| FY Dec 2023 | -41.3% |
| FY Dec 2022 | -39.4% |
| FY Dec 2021 | -61.0% |
| Jun 2026 | -140.7% |
| Mar 2026 | -111.7% |
| Dec 2025 | -134.3% |
| Sep 2025 | -81.0% |
| Jun 2025 | -64.0% |
| Mar 2025 | -55.0% |
| Dec 2024 | -69.3% |
| Sep 2024 | -49.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LRMR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$154.6M
market value at close 2026-10-26 on 2026-08-02 shares, plus long-term debt only, 2019-12-31 (79 months older than the period end), minus cash 2026-06-30
Enterprise value LRMR
| FY Dec 2025 | $255.2M |
| FY Dec 2024 | $228.3M |
| FY Dec 2023 | $187.6M |
| FY Dec 2022 | $166.4M |
| FY Dec 2021 | $135.5M |
| Jun 2026 | $238.7M |
| Mar 2026 | $304.1M |
| Dec 2025 | $255.2M |
| Sep 2025 | $200.9M |
| Jun 2025 | $179.0M |
| Mar 2025 | $131.1M |
| Dec 2024 | $228.3M |
| Sep 2024 | $397.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield LRMR
| FY Dec 2025 | -28.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -28.3% |
| Sep 2025 | -33.5% |
| Jun 2025 | -50.0% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LRMR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M |
| EPS (diluted) | n/a | -1.32 | -0.84 | -1.37 |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M |
| Cash | $85.4M | $33.2M | $26.7M | $26.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
LRMR Stock Sonar score 5/7 axes
Find similar shapesCompareLRMR ranks highest on insider conviction (68th percentile) and institutional and government (68th), and lowest on profitability (22nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LRMR filings, in plain words
Are Larimar Therapeutics insiders buying or selling LRMR?
In the 180 days to 2026-10-28, Larimar Therapeutics insiders were net buyers, a net $166.9K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Larimar Therapeutics insiders were net buyers of LRMR, a net $166.9K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
